• SNT-5505 myelofibrosis data selected for presentation at EHA 2025 Congress
• Acceleration of skin scarring program with SNT-9465 Phase 1a/b trial
• New imaging analysis reveals biological and structural normalisation of established scars

Syntara Ltd, a clinical-stage drug development company, has provided a summary of its activities for the quarter ended 31 March 2025. The company's lead program, evaluating SNT-5505 in myelofibrosis, has been selected for a presentation at the upcoming European Haematology Association (EHA) 2025 Congress. The latest interim results from the Phase 2 trial will be presented, following the initial data presented at the American Society of Hematology (ASH) meeting in 2024. The company also announced the expansion of its skin scarring program through the development of a new topical anti-fibrotic drug candidate, SNT-9465. A Phase 1a/b clinical trial will begin in Q2 2025, initially evaluating safety and tolerability in healthy volunteers, followed by an open-label study examining the drug's effectiveness in improving the physical and cosmetic properties of hypertrophic scars. Additionally, the company released new clinical data from a subgroup analysis of the SOLARIA2 Phase 1c trial, supporting the impact of its topical pan-lysyl oxidase inhibitor, SNT-6302, on remodelling established scars. The analysis, which incorporated advanced imaging technology, revealed that SNT-6302-treated scars began to resemble the structural and vascular profile of normal, uninjured skin. Syntara also provided updates on the ongoing Phase 2a iRBD study, a presentation at the NWR Virtual Healthcare Conference, and the appointment of a new Company Secretary.

Syntara ended the quarter with a strong cash position of $18 million, with the majority of the $3.13 million in net operating cash outflows during the quarter representing expenditure on the company's ongoing major clinical programs, including the Phase 2a myelofibrosis trial and the iRBD clinical trial.

Syntara remains well positioned to advance its programs with key milestones pending and within its cash runway, despite the broader volatility and uncertainty in the biotechnology sector and capital markets. The company is focused on delivering on its clinical and strategic objectives, including the upcoming presentation of SNT-5505 myelofibrosis data at the EHA 2025 Congress and the progression of its skin scarring program with the Phase 1a/b trial for SNT-9465.